Cyclophosphamide + Epidoxorubicin + Fluorouracil + Methotrexate + Mitomycin-C + Vincristine + Vindesine

This seven-drug combination chemotherapy regimen, "cyclophosphamide + epidoxorubicin + fluorouracil + methotrexate + mitomycin-c + vincristine + vindesine," is described as a multi-agent regimen primarily for advanced breast cancer. The provided search results indicate that while this exact combination is not specifically mentioned, there are references to similar combination therapies that include several of these agents. Related regimens mentioned include: * **VAM** (Vincristine, Adriamycin/Doxorubicin, and Mitomycin): Studied in advanced breast cancer patients previously treated with CMF. It showed a 31% response rate in patients who failed prior CMF, with higher rates (53%) for those failing adjuvant CMF compared to those failing CMF for advanced disease (14%). Myelosuppression was moderate, and no cardiac toxicity was observed. * **VEMFAH** (Vincristine, Cyclophosphamide (Endoxan), Methotrexate, 5-Fluorouracil, Adriamycin (Doxorubicin), and Prednisolone): Demonstrated a 77.1% overall response rate (4 complete, 23 partial responses among 35 evaluable cases) in advanced breast cancer. Median survival for responders was 27.0 months vs. 10.3 months for non-responders. Therapy was rarely terminated due to side effects, though 2 patients developed myocardial damage, but cumulative cardiotoxicity was not apparent. * **CMF** (Cyclophosphamide, Methotrexate, and Fluorouracil): A standard regimen often used as first-line or adjuvant therapy. The specific seven-drug combination would likely have a complex toxicity profile, given the number of cytotoxic agents. Potential adverse effects include myelosuppression, cardiotoxicity, neurotoxicity, mucositis, and other common chemotherapy-related toxicities.